Chronic Sialorrhea in Adults


  • Poor oral and facial muscle control
  • Parkinson's disease
  • Cerebral palsy
  • Intellectual disability
  • Stroke


  • Excessive wetness
  • Skin breakdown around the mouth
  • Infection from skin breakdown
  • Dehydration or not enough fluids
  • Foul odor
XEOMIN is the first and only FDA-approved botulinum toxin
type A for adults with chronic sialorrhea, which impacts an
estimated 600,000 adults in the United States1,3-8

Impact on Daily Living5

Closeup of chin and neck area

Interior effects

  • Risk of breathing problems or clogged airway
  • Swallowing or feeding difficulties

Exterior effects

  • Greater risk of infection
  • Skin irritation


  1. Kalf JG, de Swart BJ, Borm GF, Bloem BR, Munneke M. Prevalence and definition of drooling in Parkinson's disease: a systematic review. J Neurol. 2009;256(9):1391-1396.
  2. Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. Am Fam Physician. 2004;69(11):2628-2634.
  3. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Movement Disord. 2013;28(3):311-318.
  4. Centers for Disease Control and Prevention. Prevalence and most common causes of disability among adults - United States, 2005. MMWR Weekly. 2009;58(16):421-426. Updated April 30, 2009. Accessed June 18, 2021.
  5. Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. 2012;11:CD008624.
  6. Tiigimäe-Saar J, Taba P, Tamme T. Does Botulinum neurotoxin type A treatment for sialorrhea change oral health? Clin Oral Invest. 2017;21(3):795-800.
  7. What is ALS? ALS Association website: Accessed June 18, 2021.
  8. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2021.